SCOLR Pharma (DDD) Engages HealthPro BioVentures to Review Strategic Alternatives
SCOLR Pharma, Inc. (AMEX: DDD) announced the engagement of HealthPro BioVentures LLC, a life sciences investment bank and strategic advisory firm, as its financial advisor in connection with the evaluation of various prospective transactions, and identifying and evaluating potential strategic partners.
"We are excited about HealthPro joining our team. This is an important step in our continuing efforts to maximize the value of our CDT(R) technologies," said President and CEO Bruce S. Morra, Ph.D. "For the past several months, SCOLR has been exploring a number of strategic partnering opportunities and its Board of Directors has concluded that there is substantial benefit to be realized from retaining a financial advisor to assist in the continuation of these efforts. We have therefore engaged HealthPro, a firm with extensive relationships in the pharmaceutical industry and whose sole focus is on the life sciences sector."
SCOLR Pharma, Inc. is a specialty pharmaceutical company whose objective is to combine its formulation expertise and its patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products.[SM]
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
-0.31Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
